XML 66 R56.htm IDEA: XBRL DOCUMENT
v3.21.2

License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Oct. 31, 2020 | Feb. 28, 2021 | Nov. 30, 2020 | May 31, 2019 | Sep. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2021 | Mar. 23, 2017
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Exercised Investment Right and Purchased |  |  |  |  |  |  | $ 10,000,000.0 |
Estimated fair value of the CVR liability |  |  |  |  | $ 0 |  | 0 |
Funding Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Qualifying expenses |  |  |  |  |  |  | 300,000 |
National Institute of Health |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Grant term |  |  |  | 5 years |  |  |  |
Grants receivable |  |  |  | $ 1,500,000 |  |  |  |
Qualifying expenses |  |  |  |  | 36,000 |  |  |
Qualifying expenses on cumulative basis |  |  |  |  |  |  | 1,300,000 |
National Institute of Health | Funding Agreement |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Qualifying expenses |  |  |  |  |  | $ 0 | 500,000 |
Qualifying expenses on cumulative basis |  |  |  |  |  |  | 1,300,000 |
Contingent Value Rights Agreement | C O V I D19 |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Total fees and expenses related to clinical trials | $ 1,100,000 |  |  |  |  |  | 3,000,000.0 |
Post Exposure Prophylaxis in adults |  | In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment |  |  |  |  |  |
Increase decrease in estimated fair value of CVR liability |  |  | $ 400,000 |  |  |  |  |
Estimated fair value of the CVR liability |  |  | $ 600,000 |  | $ 0 |  | $ 0 |
Novartis License Agreement | Novartis International Pharmaceutical Ltd. |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
License agreement termination description |  |  |  |  |  |  | The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days’ prior written notice. |
Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum |  |  |  |  |  |  |  |
Research And Development Arrangement Contract To Perform For Others [Line Items] |  |  |  |  |  |  |  |
Aggregate amount payable upon satisfaction of clinical milestones |  |  |  |  |  |  |  | $ 4,300,000
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved |  |  |  |  |  |  |  | 24,000,000
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved |  |  |  |  |  |  |  | 18,000,000
Aggregate amount payable upon satisfaction of commercial milestones |  |  |  |  |  |  |  | $ 125,000,000

X
- Definition Estimated fair value of CVR liability. + References No definition available. + Details
Name: | acet_EstimatedFairValueOfCVRLiability
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Exercised Investment Right and Purchased + References No definition available. + Details
Name: | acet_ExercisedInvestmentRightAndPurchased
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fees and expense incurred in connection with clinical trials. + References No definition available. + Details
Name: | acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Grant term. + References No definition available. + Details
Name: | acet_GrantTerm
Namespace Prefix: | acet_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in estimated fair value of cvr liability. + References No definition available. + Details
Name: | acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement milestone payments upon satisfaction of clinical milestones payable. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of commercial milestones payable. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved. + References No definition available. + Details
Name: | acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License agreement termination description. + References No definition available. + Details
Name: | acet_LicenseAgreementTerminationDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Post Exposure Prophylaxis in adults + References No definition available. + Details
Name: | acet_PostExposureProphylaxisDescription
Namespace Prefix: | acet_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Qualifying expenses. + References No definition available. + Details
Name: | acet_QualifyingExpenses
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition qualifying expenses on cumulative basis. + References No definition available. + Details
Name: | acet_QualifyingExpensesOnCumulativeBasis
Namespace Prefix: | acet_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_GrantsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=acet_ResearchFundingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_ContingentValueRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NovartisInternationalPharmaceuticalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |